Brisbane, Australia, 1 September 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is today pleased to announce that ResAppDx, ResApp’s smartphone-based acute respiratory diagnostic test, is continuing to be used at a federal government-funded COVID-19 respiratory clinic in Brisbane. As the COVID-19 pandemic continues, ResApp has agreed to extend the clinic’s no-cost license to use ResAppDx (ASX: 11 May 2020) for a further three months.
Health Hub Doctors Morayfield was one of the first respiratory clinics established with federal government funding to take pressure off local hospitals by treating mild-moderate respiratory illnesses and assessing patients requiring COVID-19 testing. The clinic sees up to 300 patients per day and has 65 general practitioners and specialists on staff.
ResAppDx is being used by doctors at the clinic to triage patients who present with respiratory symptoms, helping identify illnesses such as lower respiratory tract infections, pneumonia, asthma exacerbations and COPD exacerbations.
“ResAppDx is a revolutionary tool for triaging respiratory patients,” said Dr Evan Jones, Director of Health Hub Doctors Morayfield and Adjunct Associate Professor of the University of the Sunshine Coast. “Our clinicians have found the test very useful in both confirming their suspected diagnosis as well as identifying cases otherwise not detected by a physical examination.”
“We are pleased to see the clinic find ResAppDx both useful and accurate in the evaluation of patients with respiratory symptoms during the COVID-19 pandemic,” added Tony Keating, CEO and Managing Director of ResApp. “The continued use of ResAppDx in the clinic is providing us with valuable real-world evidence on the benefits of ResAppDx, and the clinic has additionally agreed to share and publish this evidence with the medical community.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.